98 results
Page 2 of 5
6-K
EX-99.1
0icsqjs
27 Jul 22
ObsEva Announces Corporate Updates
7:03am
6-K
EX-99.3
o6rjruyrvspn5xaa
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.2
n6xk xhfsteo
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
upv8pve d4pd5h75wq5w
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
2ymcbj v6
22 Mar 22
Current report (foreign)
7:28am
6-K
EX-99.1
s0ucskl7
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
424B7
vx8sw743aoiet0 sj5p
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
EX-4.1
epp wx4mpord
17 Feb 22
Shelf registration (foreign)
4:14pm
F-3
xqsstygn0rc6ppiys
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.1
2vcpoyk11a2sql
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
424B7
5762t8 9say64
23 Nov 21
Prospectus with selling stockholder info
4:06pm
6-K
EX-99.2
9nh4ki98as f1car9mi
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
F-3
anukr
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.2
04x f5nv3q2m
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.2
1wrzjo9q j2
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.2
sxey wnsd
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am